http://www.fda.gov/cder/orange/appendix_a.txt ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL INTENSOL,...
FDA Drug Approvals List April 2000 - Drug Approvals for April 2000 Definitions and Notes Original New Drug Applications Original Application #: 021025 Approval Date: 21-APR-00 Trade Name: EXELON Chemical Type: 3 Therapeutic Potential: S Dosage Form: SOLUTION Applicant: NOVARTIS PHARMACEUTICALS CORP Active Ingredient(s): RIVASTIGMINE TARTRATE OTC/RX Status: RX Indication(s): For the treatment of mild to moderate...
Medicinal Products with a Community Marketing authorisation - Status October 2002 List The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit Medicinal Products with a Community Marketing authorisation Status: October 2002 Product Brandname INN Part A/ B Company Name Origin Therapeutic Area ATC Indication Presentation Form Strengths Number ...
author: EMEA
subject: List
Company Profile - Products That Make A Difference Lilly Trademark Chemical Identity/ Generic Name For Treatment of Actos® pioglitazone hydrochloride* for type 2 diabetes Alimta® pemetrexed for malignant pleural esothelioma for second-line treatment of non-small-cell lung cancer Byetta™ exenatide injection** for type 2 diabetes Ceclor® cefaclor for infections Cialis® tadalafil*** for male erectile dysfunction...
Milestones in Medical Research back to the top Lilly trademarks, product generic name or chemical entity, and producing company listed on this Web site Actos® (pioglitazone hydrochloride, Takeda) Alimta® (pemetrexed, Lilly) Ceclor® (cefaclor, Lilly) Cialis® (tadalafil, ICOS), Lilly-ICOS LLC Coban® (monensin sodium, Elanco) Dobutrex® (dobutamine hydrochloride, Lilly) Evista® (raloxifene...
Insulin for type 1 and type 2 diabetes - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Insulin for type 1 and type 2 diabetes - [Medication] - Quest Diagnostics Patient Health Library Insulin for type 1 and type 2 diabetes - [Medication] - Quest Diagnostics Patient Health Library Diabetes, Hormones, Adult Diabetes, adult onset...
Insulin for gestational diabetes - [Medication] - Quest Diagnostics Patient Health Library One study found that insulin lispro, a rapid-acting insulin, worked as well as human insulin and may be an option for women with gestational diabetes.Insulin's effects are felt more quickly when rapid-acting insulins (human regular aspart [Humalog] and insulin lispro) are mixed with NPH than when regular insulin is mixed...
Products Home | Search | Contact - - Products | R&D | News | About | Careers | Investors - Products Access to Medicines Women's Health Conditions & Diseases - For additional navigation you must have JavaScript enabled.
http://www.lilly.com/about/citizenship/LillyCCR2004_0705.pdf S.) Humalog ® insulin lispro injection (rDNA origin) for treatment of type 1 and type 2 diabetes Humatrope ® somatropin (rDNA origin) for injection for growth failure caused by pediatric growth hormone deficiency, for replacement therapy for adult growth hormone deficiency, for short stature caused by Turner syndrome, for idiopathic short stature Humulin &...
http://www.lilly.com/about/citizenship/LillyCCR2004_0705.pdf page 10
BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through - - - - BioNews BioWeb Companies Products BioReports - - - - - - BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials FDA APPROVED Novo Nordisk (NYSE: NVO) received a supplementary approval from the FDA allowing use of its rapid-acting insulin analog, NovoLog (recombinant insulin aspart), with external insulin pumps.
BioPortfolio Limited 48 Antithrombotics in development for acute ischemic stroke 49 ReoPro (abciximab) 49 Retavase (reteplase) 52 Chapter 3 Alzheimer’s disease 56 Summary 56 Disease overview 57 Epidemiology 59 Market analysis 61 Aricept (donepezil) 63 Exelon (rivastigmine) 66 Reminyl (galantamine) 68 Ebixa (memantine) 70 Late-stage pipeline analysis 72 Cere (cerebrolysin) 75 COGNIShunt 77 NS-2330 79...
BioPortfolio Limited 70 Main types of dyslipidemia 73 Hypercholesterolemia 73 Familial hypercholesterolemia 74 Hypertriglyceridemia 74 Familial hypertriglyceridemia 74 Mixed dyslipidemia 75 Epidemiology 75 Drug therapy 78 Statins 79 Fibrates 80 Bile acid sequestrants/inhibitors 81 Nicotinic acid derivatives 82 Fish oil derivatives 82 Market analysis 82 Lipitor (atorvastatin) 84 Zocor (simvastatin) 87...
BioPortfolio Limited 39 Chapter 2 Erythropoietins 44 Summary 44 Class overview 44 Mechanism of action 46 Global sales 46 Analysis of leading products 47 Procrit/Eprex (epoetin alpha) 47 Epogen (epoetin alpha) and Aranesp (darbepoetin alpha) 50 NeoRecormon/Epogin (epoetin beta) 52 Late stage R&D activity 53 Hemolink (hemoglobin raffimer) 54 Chapter 3 Interferons 56 Summary 56 Class overview 57 Mechanism...
http://www.lilly.com/investor/annual_report/lillyar2004complete.pdf page 96
PowerPoint Presentation Novo Nordisk market share 31% 59% 75% 48% World Japan Europe US Market 42% 47% 5% Market size 100% 10.4% 9.1% 7.7% 18.0% 6.5% 10.7% 6.9% 5.8% Novo Nordisk Growth rates A continued increase in market share Source: IMS/BW Note: Quarterly data, volume figures Q1 2000 Q3 2003 Q1 2000 Q3 2003 Analogue penetration Novo Nordisk’s analogue market share Analogues Human insulin 28%...
author: Nanna Poulsen
Endocrinologic and Metabolic Drugs Advisory Committee Meetings FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - Endocrinologic and Metabolic Drugs Advisory Committee Meetings List of Tentative Meeting Dates for All CDER Advisory Committees List of Committee Members Committee Charter CDER Contacts Current Year Meeting Information 2004 FDA Advisory Committee Calendar - Meeting information includes...
Microsoft Word - Supp 036 AP letter.doc page 1
author: RHEEJ
No Slide Title Submitted to Diabetes, Obesity and Metabolism Asakura T & Seino H Diabetes Metab 2003;29:4S236 Comparison of FlexPen® with Humalog ® KitTM Days 4 2 0 FlexPen® FlexPen® Humalog ® KitTM Humalog ® KitTM Run-in (n = 58) ”Device-naive” patients Both pens contained rapid-acting analogues, however, no insulin was injected during...
author: S&H Sam
Welcome to Lilly UK - Humalog Generic Name: - Insulin Lispro - Legal Category: - POM Product Strengths: - 100iu/ml - Product Forms: - Pre-filled pens, vials, cartridges - Presentations: - 3ml x 5 Cartridges 3ml Pre-filled pen 10ml x 1 Vial - - Product Codes - PIP Code - EAN Code - Licence Cartridge 3ml x 5 - 248 - 7486 - 5014602101046 - EU/1/96/007/004 Pen 3ml x 5 - 271 - 0507 - 5014602101145 - EU/1/96...
http://www.novonordisk.com/images/diabetes/pdf/novorapid_pump2.pdf Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion A randomized study in type 1 diabetes BRUCE BODE, MD 1 RICHARD WEINSTEIN, MD 2 DAVID BELL, MD 3 JANET MCGILL, MD 4 DANIEL NADEAU, MD 5 PHILIP RASKIN, MD 6 JAIME DAVIDSON, MD 7 ROBERT HENRY, MD 8 WON- CHIN HUANG, PHD 9 RICKEY R.
duplicates:http://www.novonordisk.com/images/diabetes/pdf/novorapid_nocturnalhypoglycaemia.pdf http://www.novonordisk.com/images/diabetes/pdf/novorapid_hypoglycaemiacontrol.pdf http://www.novonordisk.com/images/diabetes/pdf/novorapid_longtermcontrol.pdf
http://www.novonordisk.com/images/diabetes/pdf/novorapid_pump2.pdf page 2
duplicates:http://www.novonordisk.com/images/diabetes/pdf/novorapid_nocturnalhypoglycaemia.pdf http://www.novonordisk.com/images/diabetes/pdf/novorapid_hypoglycaemiacontrol.pdf http://www.novonordisk.com/images/diabetes/pdf/novorapid_longtermcontrol.pdf
http://www.novonordisk.com/images/diabetes/pdf/novorapid_pump1.pdf At the screening visit, patients were supplied with infusion sets (Sof- set canula 42" MMT- 315, reservoir 3 ml MMT- 103; MiniMed, Sylamar, CA) and instructed to continue using their own infusion pump (MiniMed models 506, 507, or 507C) and their current CSII insulin (all patients were using insulin lispro, Humalog; Eli Lilly, Indianapolis, IN) until the...
http://www.novonordisk.com/images/diabetes/pdf/novorapid_pump1.pdf page 2
Product Monograph Insulin receptor affinity (%) 100 92 ± 6 84 ± 6 Human insulin NovoRapid ® Insulin lispro Insulin receptor off- rate (%) 100 81 ± 8 100 ± 11 Metabolic potency (lipogenesis) (%) 100 101 ± 2 82 ± 3 IGF- 1 receptor affinity (%) 100 81 ± 9 156 ± 16 Mitogenic potency (%) 100 58 ± 22 66 ± 10 Table 1 21...
author: S&H Sam
